Personal Values and Pain Tolerance: Does a Values Intervention Add to Acceptance?

Previous research suggests that acceptance is a promising alternative to distraction and control techniques in successfully coping with pain. Acceptance interventions based upon Acceptance and Commitment Therapy (ACT) have been shown to lead to greater tolerance of acute pain as well as increased adjustment and less disability among individuals with chronic pain. However, in these previous intervention studies, the ACT component of values has either not been included or not specifically evaluated. The current study compares the effects of an ACT-based acceptance intervention with and without the values component among individuals completing the cold-pressor task. Results indicate that inclusion of the values component (n = 34) of ACT leads to significantly greater pain tolerance than acceptance alone (n = 30). Consistent with previous research, both conditions were associated with greater pain tolerance than control (n = 35). Despite the difference in tolerance, pain threshold did not differ, and participants in the control condition provided lower ratings of pain severity. The findings from this study support the important role of values and values clarification in acceptance-based interventions such as ACT, and provide direction for clinicians working with individuals with chronic pain conditions.PerspectiveThis article evaluates the additive effect of including a personalized-values exercise in an acceptance-based treatment for pain. Results indicate that values interventions make a significant contribution and improvement to acceptance interventions, which may be of interest to clinicians who provide psychological treatment to individuals with chronic pain.     

Uncommon single and compound EGFR mutations: clinical outcomes of a heterogeneous subgroup of NSCLC

Molecular characterization of non-small-cell lung cancer (NSCLC) is essential to define the correct therapeutic algorithm in metastatic disease. Approximately 90% of epidermal growth factor receptor (EGFR) mutations are usually associated with sensitivity to EGFR tyrosine kinase inhibitors (TKIs). The remaining 10% defines a small, extremely heterogeneous subgroup of mutations, with a varied profile of sensitivity and response to target therapies.This retrospective observational study includes 47 patients affected by metastatic NSCLC harboring uncommon EGFR mutations (single or compound mutation). Patients were treated with EGFR-targeting TKIs or platinum-based chemotherapy as first-line treatment.Median OS resulted longer in the compound mutation group when compared to single rare mutations (33.6 vs 12 months; P = 0.473); a similar result was observed for PFS (16 vs 7.6 months; P = 0.281), although statistical significance was not reached. ORR, PFS and OS resulted similar for patients treated with first-line EGFR TKIs or chemotherapy. No difference in terms of PFS and OS was found according to the TKI administered.Compound mutations seem to be a good prognostic indicator for OS; they are also predictive of response to 1st and 2nd generation EGFR TKIs, as well as exon 19 insertions and mutations in codon 719 of exon 18. For mutations in exon 18 (not in codon 719) and exon 20 insertions, chemotherapy seems the most effective available option. The addition of immunotherapy to chemotherapy could change this approach in the next future.     

Immunotherapy for lung cancer: Focusing on chimeric antigen receptor (CAR)-T cell therapy

Besides traditional treatment strategies, including surgery, radiotherapy, and chemotherapy for lung cancer as the leading cause of cancer incidence and death, immunotherapy has also emerged as a new treatment strategy. The goal of immunotherapy is to stimulate the immune system responses against cancer, using various approaches such as therapeutic vaccines, monoclonal antibodies, immune checkpoint inhibitors, and T-cell therapy. Chimeric antigen receptor (CAR)-T cells, one of the most popular cancer immunotherapy approaches in the last decade, are genetically engineered T-cells to redirect patients' immune responses to recognize and eliminate tumor-associated antigens (TAA)-expressing tumor cells. CAR-T cell therapy provides promising benefits in lung tumors. In this review, we summarize different immunotherapy approaches for lung cancer, the structure of CAR-T cells, currently undergoing CARs in clinical trials, and various TAAs are being investigated as potential targets in designing CAR-T cells for lung cancer.